Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Combination treatment

    Healthcare setting

    Clinical research in 2026: The trends shaping tomorrow

    Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

    Cuttsy + Cuttsy

    - PMLiVE

    Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

    Over 800,000 people worldwide live with haemophilia

    - PMLiVE

    5 key digital CX challenges in pharma, and how to start solving them

    Creating great digital experiences in pharma isn’t easy, but progress doesn’t always need to come from big projects or budgets. Here are 5 common challenges that leading digital teams are...

    Graphite Digital

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

    Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

    Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links